SB 657510Selective urotensin-II (UT) receptor antagonist CAS# 474960-44-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 474960-44-6 | SDF | Download SDF |
PubChem ID | 11272107 | Appearance | Powder |
Formula | C19H22BrClN2O5S | M.Wt | 505.81 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 2-bromo-N-[4-chloro-3-[(3R)-1-methylpyrrolidin-3-yl]oxyphenyl]-4,5-dimethoxybenzenesulfonamide | ||
SMILES | CN1CCC(C1)OC2=C(C=CC(=C2)NS(=O)(=O)C3=C(C=C(C(=C3)OC)OC)Br)Cl | ||
Standard InChIKey | KQCZCINJGIRLCD-CYBMUJFWSA-N | ||
Standard InChI | InChI=1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3/t13-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective urotensin-II (UT) receptor antagonist (Ki values are 61, 17, 30, 65 and 56 nM at human, monkey, cat, rat and mouse receptors respectively). Inhibits U-II-induced intracellular Ca2+ mobilization (IC50 = 180 nM) and antagonizes the contractile action of U-II in isolated mammalian arteries and aortae (EC50 = 50 - 189 nM). |
SB 657510 Dilution Calculator
SB 657510 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.977 mL | 9.8851 mL | 19.7703 mL | 39.5405 mL | 49.4257 mL |
5 mM | 0.3954 mL | 1.977 mL | 3.9541 mL | 7.9081 mL | 9.8851 mL |
10 mM | 0.1977 mL | 0.9885 mL | 1.977 mL | 3.9541 mL | 4.9426 mL |
50 mM | 0.0395 mL | 0.1977 mL | 0.3954 mL | 0.7908 mL | 0.9885 mL |
100 mM | 0.0198 mL | 0.0989 mL | 0.1977 mL | 0.3954 mL | 0.4943 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ST 91
Catalog No.:BCC7436
CAS No.:4749-61-5
- 2,16-Kauranediol 2-O-beta-D-allopyranoside
Catalog No.:BCN1436
CAS No.:474893-07-7
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- N-Methylsarpagine methosalt
Catalog No.:BCN5530
CAS No.:47418-70-2
- CAL-130 Racemate
Catalog No.:BCC1442
CAS No.:474012-90-3
- Brassicasterol
Catalog No.:BCN2613
CAS No.:474-67-9
- Campesterol
Catalog No.:BCN3181
CAS No.:474-62-4
- Campestanol
Catalog No.:BCN3890
CAS No.:474-60-2
- Daucosterol
Catalog No.:BCN5531
CAS No.:474-58-8
- Reserpin N-oxide
Catalog No.:BCN3493
CAS No.:474-48-6
- Citrostadienol
Catalog No.:BCN7357
CAS No.:474-40-8
- Chenodeoxycholic acid
Catalog No.:BCN2620
CAS No.:474-25-9
- H-N-Me-Pro-OH
Catalog No.:BCC3351
CAS No.:475-11-6
- (+)-Isocorynoline
Catalog No.:BCN2361
CAS No.:475-67-2
- Liriodenine
Catalog No.:BCN5532
CAS No.:475-75-2
- Aristolochic acid B
Catalog No.:BCN6263
CAS No.:475-80-9
- Glaucine
Catalog No.:BCN2550
CAS No.:475-81-0
- Nuciferine
Catalog No.:BCN1223
CAS No.:475-83-2
- NS 304
Catalog No.:BCC7661
CAS No.:475086-01-2
- Tivozanib (AV-951)
Catalog No.:BCC1179
CAS No.:475108-18-0
- ZSTK474
Catalog No.:BCC3657
CAS No.:475110-96-4
- Galnon
Catalog No.:BCC5871
CAS No.:475115-35-6
- BAN ORL 24
Catalog No.:BCC1398
CAS No.:475150-69-7
- 2-Methylthioadenosine diphosphate trisodium salt
Catalog No.:BCC5794
CAS No.:475193-31-8
Fate and chemical speciation of antimony (Sb) during uptake, translocation and storage by rye grass using XANES spectroscopy.[Pubmed:28935406]
Environ Pollut. 2017 Dec;231(Pt 2):1322-1329.
Antimony (Sb) is a contaminant of increased prevalence in the environment, but there is little knowledge about the mechanisms of its uptake and translocation within plants. Here, we applied for the synchrotron based X-ray absorption near-edge structure (XANES) spectroscopy to analyze the speciation of Sb in roots and shoots of rye grass (Lolium perenne L. Calibra). Seedlings were grown in nutrient solutions to which either antimonite (Sb(III)), antimonate (Sb(V)) or trimethyl-Sb(V) (TMSb) were added. While exposure to Sb(III) led to around 100 times higher Sb accumulation in the roots than the other two treatments, there was no difference in total Sb in the shoots. Antimony taken up in the Sb(III) treatment was mainly found as Sb-thiol complexes (roots: >76% and shoots: 60%), suggesting detoxification reactions with compounds such as glutathione and phytochelatins. No reduction of accumulated Sb(V) was found in the roots, but half of the translocated Sb was reduced to Sb(III) in the Sb(V) treatment. Antimony accumulated in the TMSb treatment remained in the methylated form in the roots. By synchrotron based XANES spectroscopy, we were able to distinguish the major Sb compounds in plant tissue under different Sb treatments. The results help to understand the translocation and transformation of different Sb species in plants after uptake and provide information for risk assessment of plant growth in Sb contaminated soils.
Occurrence of selected elements (Ti, Sr, Ba, V, Ga, Sn, Tl, and Sb) in deposited dust and human hair samples: implications for human health in Pakistan.[Pubmed:29022181]
Environ Sci Pollut Res Int. 2018 May;25(13):12234-12245.
The current study determined, for the first time, the levels of titanium (Ti), strontium (Sr), barium (Ba), vanadium (V), gallium (Ga), tin (Sn), thallium (Tl), and antinomy (Sb), in deposited dust, and human hair collected from general population of different geographical areas of Pakistan. All the samples were prepared by microwave digestion and measured by ICP-MS. The results showed that on deposited dust samples, the detected elements followed the descending trend as: Ti > Sr > Ba > V > Ga > Sn > Tl > Sb similar to the upper continental crust. The deposited dust samples from low elevation areas exhibited highest levels of all studied elements (except antimony which was higher in soil samples from mountainous areas), followed by rive plains, mountainous areas, and highland valleys. In contrast, on human hair samples, the elements followed the descending trend as: Sr > Ba > Ti > Ga > V > Sn > Sb > Tl respectively. Ba, Ga, and V concentrations were higher in soil samples from lower elevation Indus plain, and Sr, Tl, Sb, and Ti were higher in samples from mountainous areas. The bioaccumulation trend of all studied elements was in descending order as follows: Sb, Ga, Sn, Ba, Sr, Ti, V, Tl, respectively. Principal component analysis (PCA) and correlation matrix evidenced both geological influences and anthropogenic activities as potential sources of these studied elements. On the other hand, the risk estimation (HI > 1) concluded that population were at higher health risk (non-carcinogenic) for Ga and Ti. All other studied rare elements were within safe limit for humans from all zones.
Lead-free perovskite solar cells using Sb and Bi-based A3B2X9 and A3BX6 crystals with normal and inverse cell structures.[Pubmed:28989856]
Nano Converg. 2017;4(1):26.
Research of CH3NH3PbI3 perovskite solar cells had significant attention as the candidate of new future energy. Due to the toxicity, however, lead (Pb) free photon harvesting layer should be discovered to replace the present CH3NH3PbI3 perovskite. In place of lead, we have tried antimony (Sb) and bismuth (Bi) with organic and metal monovalent cations (CH3NH3(+), Ag(+) and Cu(+)). Therefore, in this work, lead-free photo-absorber layers of (CH3NH3)3Bi2I9, (CH3NH3)3Sb2I9, (CH3NH3)3SbBiI9, Ag3BiI6, Ag3BiI3(SCN)3 and Cu3BiI6 were processed by solution deposition way to be solar cells. About the structure of solar cells, we have compared the normal (n-i-p: TiO2-perovskite-spiro OMeTAD) and inverted (p-i-n: NiO-perovskite-PCBM) structures. The normal (n-i-p)-structured solar cells performed better conversion efficiencies, basically. But, these environmental friendly photon absorber layers showed the uneven surface morphology with a particular grow pattern depend on the substrate (TiO2 or NiO). We have considered that the unevenness of surface morphology can deteriorate the photovoltaic performance and can hinder future prospect of these lead-free photon harvesting layers. However, we found new interesting finding about the progress of devices by the interface of NiO/Sb(3+) and TiO2/Cu3BiI6, which should be addressed in the future study.
Influence of weak magnetic field and tartrate on the oxidation and sequestration of Sb(III) by zerovalent iron: Batch and semi-continuous flow study.[Pubmed:28968561]
J Hazard Mater. 2018 Feb 5;343:266-275.
The influence of weak magnetic field (WMF) and tartrate on the oxidation and sequestration of Sb(III) by zerovalent iron (ZVI) was investigated with batch and semi-continuous reactors. The species analysis of antinomy in aqueous solution and solid precipitates implied that both Sb(III) adsorption preceding its conversion to Sb(V) in solid phase and Sb(III) oxidation to Sb(V) preceding its adsorption in aqueous phase occurred in the process of Sb(III) sequestration by ZVI. The application of WMF greatly increased the rate constants of Sbtot (total Sb) and Sb(III) disappearance during Sb(III)-tartrate and uncomplexed-Sb(III) sequestration by ZVI. The enhancing effect of WMF was primarily due to the accelerated ZVI corrosion in the presence of WMF, as evidenced by the influence of WMF on the change of solution and solid properties with reaction. However, tartrate greatly retarded Sb removal by ZVI. It was because tartrate inhibited ZVI corrosion, competed with Sb(III) and Sb(V) for the active surface sites, increased the negative surface charge of the generated iron (hydr)oxides due to its adsorption, and formed soluble complexes with Fe(III). The positive effect of WMF on Sb(III)-tartrate and uncomplexed-Sb(III) removal by ZVI was also verified with a magnetic semi-continuous reactor.
Structural and Optical Properties of Sb-Substituted BiSI Grown from Sulfur/Iodine Flux.[Pubmed:28967746]
Inorg Chem. 2017 Oct 16;56(20):12362-12368.
Bismuth and antimony were reacted in sulfur/iodine flux mixtures at various temperatures and iodine concentrations to explore the effects of these variables on the synthesis and properties of Bi1-xSbxSI products. The products grow as crystals; microprobe elemental analysis and UV/vis/NIR spectroscopy of the Bi1-xSbxSI solid solutions indicate that substitution is homogeneous within individual crystals but varies up to 15% between crystals within each synthesis batch. Raman spectra show a two-mode behavior upon substitution, indicating covalent bonding within the structure, and TEM/SEM data confirm no presence of nanoclustering or segregation within the crystals.
Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.[Pubmed:18587423]
Br J Pharmacol. 2008 Oct;155(3):374-86.
BACKGROUND AND PURPOSE: The recent development of the UT ligand palosuran (1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulphate salt) has led to the proposition that urotensin-II (U-II) plays a significant pathological role in acute and chronic renal injury in the rat. EXPERIMENTAL APPROACH: In the present study, the pharmacological properties of palosuran were investigated further using a series of radioligand binding and functional bioassays. KEY RESULTS: Palosuran functioned as a 'primate-selective' UT ligand in recombinant cell membranes (monkey and human UT K(i) values of 4 +/- 1 and 5 +/- 1 nM), lacking appreciable affinity at other mammalian UT isoforms (rodent and feline K(i) values >1 microM). Paradoxically, however, palosuran lost significant (10- to 54-fold) affinity for native and recombinant human UT when radioligand binding was performed in intact cells (K(i) values of 50 +/- 3 and 276 +/- 67 nM). In accordance, palosuran also exhibited diminished activity in hUT (human urotensin-II receptor)-CHO (Chinese hamster ovary) cells (IC50 323 +/- 67 nM) and isolated arteries (K(b)>10 microM in rat aorta; K(b)>8.5 microM in cat arteries; K(b)>1.6 microM in monkey arteries; K(b) 2.2 +/- 0.6 microM in hUT transgenic mouse aorta). Relative to recombinant binding K(i) values, palosuran was subjected to a 392- to 690-fold reduction in functional activity in monkey isolated arteries. Such phenomena were peculiar to palosuran and were not apparent with an alternative chemotype, SB-657510 (2-bromo-N-[4-chloro-3-((R)-1-methyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dimethoxyben zenesulphonamide HCl). CONCLUSIONS AND IMPLICATIONS: Collectively, such findings suggest that caution should be taken when interpreting data generated using palosuran. The loss of UT affinity/activity observed in intact cells and tissues cf. membranes offers a potential explanation for the disappointing clinical efficacy reported with palosuran in diabetic nephropathy patients. As such, the (patho)physiological significance of U-II in diabetic renal dysfunction remains uncertain.
Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.[Pubmed:15852036]
Br J Pharmacol. 2005 Jul;145(5):620-35.
1. SB-706375 potently inhibited [(125)I]hU-II binding to both mammalian recombinant and 'native' UT receptors (K(i) 4.7+/-1.5 to 20.7+/-3.6 nM at rodent, feline and primate recombinant UT receptors and K(i) 5.4+/-0.4 nM at the endogenous UT receptor in SJRH30 cells). 2. Prior exposure to SB-706375 (1 microM, 30 min) did not alter [(125)I]hU-II binding affinity or density in recombinant cells (K(D) 3.1+/-0.4 vs 5.8+/-0.9 nM and B(max) 3.1+/-1.0 vs 2.8+/-0.8 pmol mg(-1)) consistent with a reversible mode of action. 3. The novel, nonpeptidic radioligand [(3)H]SB-657510, a close analogue of SB-706375, bound to the monkey UT receptor (K(D) 2.6+/-0.4 nM, B(max) 0.86+/-0.12 pmol mg(-1)) in a manner that was inhibited by both U-II isopeptides and SB-706375 (K(i) 4.6+/-1.4 to 17.6+/-5.4 nM) consistent with the sulphonamides and native U-II ligands sharing a common UT receptor binding domain. 4. SB-706375 was a potent, competitive hU-II antagonist across species with pK(b) 7.29-8.00 in HEK293-UT receptor cells (inhibition of [Ca(2+)](i)-mobilization) and pK(b) 7.47 in rat isolated aorta (inhibition of contraction). SB-706375 also reversed tone established in the rat aorta by prior exposure to hU-II (K(app) approximately 20 nM). 5. SB-706375 was a selective U-II antagonist with >/=100-fold selectivity for the human UT receptor compared to 86 distinct receptors, ion channels, enzymes, transporters and nuclear hormones (K(i)/IC(50)>1 microM). Accordingly, the contractile responses induced in isolated aortae by KCl, phenylephrine, angiotensin II and endothelin-1 were unaltered by SB-706375 (1 microM). 6. In summary, SB-706375 is a high-affinity, surmountable, reversible and selective nonpeptide UT receptor antagonist with cross-species activity that will assist in delineating the pathophysiological actions of U-II in mammals.